Application of phosphoethanolamine / phosphorylcholine phosphatase 1 in inhibition of retinal pigment epithelial cell ferroptosis

By overexpressing ethanolamine phosphate/phosphocholine phosphatase 1 in retinal pigment epithelial cells, the PE content in the endoplasmic reticulum was reduced, and the problem of ferric death in retinal pigment epithelial cells was solved, and effective inhibition of age-related macular degeneration was achieved. It also demonstrates the wide application potential of this technology.

CN119015446APending Publication Date: 2024-11-26TONGJI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411023029.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Ferrodynamic retinal pigment epithelial cell ferrothelial cell is an important factor leading to age-related macular degeneration. The prior art is difficult to effectively inhibit this process, resulting in treatment difficulties.

Method used

By overexpressing ethanolamine phosphate/phosphocholine phosphatase 1 (PHOSPHO1) in retinal pigment epithelial cells, the content of phosphatidylethanolamine (PE) in the endoplasmic reticulum is reduced, thereby inhibiting iron ion-catalyzed lipid peroxidation reaction and reducing cell death .

Benefits of technology

Significantly inhibiting ferrodynamic death in retinal pigment epithelial cells provides new methods for the treatment of age-related macular degeneration and demonstrates potential application value for other cellular ferrodynamic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015446A_ABST
    Figure CN119015446A_ABST
Patent Text Reader

Abstract

The invention discloses an application of phosphoethanolamine / phosphorylcholine phosphatase 1 in inhibition of ferroptosis of retinal pigment epithelial cells. The invention discloses an application of a phosphoethanolamine / phosphorylcholine phosphatase 1 gene in preparation of a medicine as shown in (1) or (2). The medicine comprises a carrier for overexpressing the phosphoethanolamine / phosphorylcholine phosphatase 1 gene; (1) a drug for inhibiting ferroptosis of retinal pigment epithelial cells; and (2) a medicine for preventing and / or treating age-related macular degeneration. The invention finds that overexpression of phosphoethanolamine / phosphocholine phosphatase 1 in RPE cells can reduce the content of phosphatidyl ethanolamine in endoplasmic reticulum so as to inhibit RPE cell ferroptosis, and can be used for treating age-related macular degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of phosphoethanolamine / phosphocholine phosphatase 1 in inhibiting ferroptosis of retinal pigment epithelial cells. Background Art

[0002] Age-related macular degeneration (AMD) is one of the main causes of severe vision loss in the elderly. The pathogenesis of AMD is complex, among which ferroptosis of retinal pigment epithelial (RPE) cells is considered to be one of the important factors leading to the onset of AMD. Ferroptosis is a form of cell death characterized by lipid peroxidation catalyzed by iron ions. It has been found that the concentration of iron ions in the retina of AMD patients is significantly increased, and anemic patients taking iron supplements show characteristics of AMD, confirming that RPE cell ferroptosis is one of the causes of AMD. Therefore, inhibiting RPE cell ferroptosis has become a research hotspot for the treatment of AMD. Summary of the invention

[0003] In order to solve the deficiencies in the prior art, the present invention aims to provide the use of phosphoethanolamine / phosphocholine phosphatase 1 in inhibiting ferroptosis of retinal pigment epithelial cells.

[0004] Ferroptosis is a form of cell death triggered by iron-catalyzed lipid peroxidation, characterized by the generation of reactive oxygen species (ROS) and the accumulation of lipid peroxidation. Non-enzymatic lipid peroxidation plays a central role in the mechanism of ferroptosis, a process that is mainly driven by free radicals, including Fe 2+ The catalytic reaction is particularly critical. Non-enzymatic lipid peroxidation is mainly induced by Fe 2+Triggered, hydrogen peroxide is catalyzed by Fenton reaction and Haber-Weiss reaction to produce hydroxyl radicals. The core event of ferroptosis is the production of lipid peroxides. Studies have shown that lipid peroxides are mainly derived from phosphatidylethanolamine (PE) in the endoplasmic reticulum. There are dozens of PE in cells according to their fatty acid side chains, and the lipid peroxides are produced by carrying PE-AA and PE-AdA molecules, not free polyunsaturated fatty acids, and PE metabolites such as malondialdehyde (MDA) and 4-hydroxynonenal (4-Hydroxynonenal, 4-HNE) can also activate cell programmed cell death-related signaling pathways. It can be seen that PE is the core molecule that produces lipid peroxides that induce ferroptosis. The present invention finds that overexpressing phosphoethanolamine / phosphocholine phosphatase 1 (PHOSPHO1) in RPE cells can reduce the PE content in the endoplasmic reticulum, thereby inhibiting RPE cell ferroptosis, which can be used to treat AMD.

[0005] The present invention overexpresses PHOSPHO1 in iPSC-RPE cells, which can reduce the content of PE in the endoplasmic reticulum of the cells, thereby inhibiting ferroptosis induced by erastin or FAC. In an in vivo rat experiment, a virus carrying the Phospho1 gene is injected into the subretinal space to infect RPE cells so that PHOSPHO1 is overexpressed, and ferroptosis is induced by injecting FAC into the vitreous cavity. The inhibitory effect of PHOSPHO1 on RPE ferroptosis is determined by detecting ERG, measuring the thickness of the nuclear layer and immunohistological staining.

[0006] The specific technical solutions of the present invention are as follows:

[0007] The present invention provides the use of the phosphoethanolamine / phosphocholine phosphatase 1 gene in the preparation of the following medicine (1) or (2), wherein the medicine comprises a vector that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene;

[0008] (1) Drugs that inhibit ferroptosis of retinal pigment epithelial cells;

[0009] (2) Drugs for preventing and / or treating age-related macular degeneration.

[0010] Furthermore, the vector is a viral vector;

[0011] Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.

[0012] Furthermore, the ferroptosis is ferroptosis induced by iron ions.

[0013] The present invention also provides a product as described in any one of the following (1)-(3),

[0014] (1) The product is a pharmaceutical composition, which comprises a vector that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene;

[0015] Preferably, the vector is a viral vector;

[0016] Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector;

[0017] (2) The product is a cell overexpressing the phosphoethanolamine / phosphocholine phosphatase 1 gene, and the cell is an iPSC-RPE cell or an RPE cell;

[0018] (3) The product is a rat that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene, and the phosphoethanolamine / phosphocholine phosphatase 1 gene is overexpressed in the RPE cells of the rat.

[0019] The present invention also provides a method for inhibiting ferroptosis of retinal pigment epithelial cells, comprising: overexpressing phosphoethanolamine / phosphocholine phosphatase 1 gene in the retinal pigment epithelial cells.

[0020] Furthermore, the phosphoethanolamine / phosphocholine phosphatase 1 gene is overexpressed in retinal pigment epithelial cells by introducing an overexpression vector carrying the phosphoethanolamine / phosphocholine phosphatase 1 gene.

[0021] Furthermore, the overexpression vector is a viral vector;

[0022] Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.

[0023] The present invention also provides a method for reducing the content of phosphatidylethanolamine in the endoplasmic reticulum of retinal pigment epithelial cells, comprising: overexpressing the phosphoethanolamine / phosphocholine phosphatase 1 gene in the retinal pigment epithelial cells.

[0024] Furthermore, the phosphoethanolamine / phosphocholine phosphatase 1 gene is overexpressed in retinal pigment epithelial cells by introducing an overexpression vector carrying the phosphoethanolamine / phosphocholine phosphatase 1 gene.

[0025] Furthermore, the overexpression vector is a viral vector;

[0026] Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.

[0027] Compared with the prior art, the present invention has the following advantages:

[0028] 1. Significant effect: By reducing the content of PE in the endoplasmic reticulum of RPE cells and reducing the production of lipid peroxides, ferroptosis can be significantly inhibited.

[0029] 2. Highly innovative: Targeting PE, directly reducing the substrates produced by lipid peroxides, thereby inhibiting RPE cell ferroptosis and protecting the retina, providing new ideas and methods for the prevention and treatment of AMD.

[0030] 3. Wide application: It has important application value in inhibiting the ferroptosis of RPE cells, and may also inhibit the ferroptosis of other cells, thus having potential application value for diseases caused by ferroptosis of cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1-4 : Overexpression of PHOSPHO1 in iPSC-RPE cells can reduce PE concentration and enhance their resistance to ferroptosis.

[0032] Figure 1 A and 1B: Overexpression of PHOSPHO1 in iPSC-RPE cells was confirmed by WB and quantitative analysis (n=3).

[0033] Figure 2 : The levels of total PE molecular species were detected by lipidomics methods, and the quantitative unit was pmol / mg, that is, the number of moles of lipid per mg of endoplasmic reticulum protein (n=3).

[0034] Figure 3 : After 48 h of ferroptosis induction, cell viability was assessed by CCK-8 (n=6).

[0035] Figure 4 : After 4 h of ferroptosis induction, the intracellular ROS level was assessed using the DCFH-DA probe (n=6).

[0036] Figure 5-7 :In vivo verification of the inhibitory effect of overexpression of PHOSPHO1 on RPE cell ferroptosis and retinal protection.

[0037] Figure 5 A and 5B: RBCC were collected 2 days after infection with lentivirus carrying rat Phospho1 gene, and the overexpression of PHOSPHO1 protein was confirmed and quantified by WB (n=3).

[0038] Figure 6 C and 6D: 3 μL of lentiviral solution was injected into the subretinal space of SD rats. After 7 days, the gene expression was stable, and then 2 μL of 2 mM FAC was injected into the vitreous cavity. ERG waveforms were recorded on the 7th day after intravitreal injection (set to 100 μV vertical scale unit and 25 ms horizontal scale unit), and the ERG a-wave and b-wave amplitudes were quantitatively analyzed (n=6).

[0039] Figure 7E and 7F: Staining of frozen sections of retinal samples and quantitative analysis of ONL thickness (n = 8). Positive transfection of lentivirus in RPE cells was indicated by GFP labeling. Overexpression of PHOSPHO1 protein in RPE cells showed better anti-ferroptosis ability than the empty vector control group, which could reduce the expression of 4-HNE and increase the thickness of the nuclear layer. DETAILED DESCRIPTION

[0040] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.

[0041] In the following examples, 293FT was purchased from ATCC; iPSC-RPE cells were differentiated by this laboratory. Induced PRE (iRPE) cells were constructed by this laboratory, using key transcription factors, and the RPE cells with anti-EMT obtained after being transferred into human iPSC-RPE cells expressed PHOSPHO1. All animal experimental procedures in the present invention were carried out in strict accordance with the guidelines established by the Animal Experiment Ethics Committee of Tongji University.

[0042] Example 1. Overexpression of PHOSPHO1 in iPSC-RPE cells inhibits cell ferroptosis

[0043] (1) Overexpression of PHOSPHO1 in iPSC-RPE cells

[0044] PHOSPHO1 gene sequence acquisition: RNA was extracted from iRPE cells and Primescript was used TMRTMaster Mix kit was used to reverse transcribe the extracted mRNA into cDNA, and PCR was used to obtain the PHOSPHO1 gene sequence. The primers used in PCR were: F: AGCGAATTCGGGATCGCCACCATGTGCCAGCGACCCTGG (SEQ ID NO.1); R: CAGATCCTTGCGGCCTCAGCACATCTTCAGCACCTGTTGC (SEQ ID NO.2). The PCR amplification reaction system included 25 μL PrimeSTARMax Premix (2×), 10 pmol of each primer F / R, 100 ng template cDNA, and ddH2O was used to make up to 50 μL total volume. PCR reaction conditions: 98℃, 10 min; 98℃, 10 s; 55℃, 15 s; 72℃, 1.5 min; 33 cycles, terminal extension 72℃, 10 min. The product was recovered by gel cutting after electrophoresis. The recovered PCR products were quantitatively analyzed using NanoDrop2000 spectrophotometer to determine DNA concentration and purity, and then stored at -20°C for a long term.

[0045] Vector construction: The PCR product was connected to the pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro vector (Wuhan Miaoling Biotechnology Co., Ltd., P0268) double-digested with ECOR1 and BAMH1 using a ready-to-use seamless cloning kit (Sangong, B632219). The connection reaction system contained 10 μL of 2X Seamless cloning MasterMix, 0.3 pmol of the target gene DNA fragment, and 0.1 pmol of the vector plasmid DNA fragment. The total volume was supplemented to 20 μL with sterilized ddH2O. The connection was carried out at 50°C for 20 minutes to promote the effective recombination connection between the target gene and the vector plasmid DNA fragment. The resulting connection plasmid was the vector plasmid pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro carrying the PHOSHO1 gene. After the connection plasmid was transformed into STBL3 competent cells, clones were selected, shaken, and plasmids were extracted.

[0046] Virus preparation and cell transfection: HEK293T cells were inoculated into a 10 cm diameter cell culture dish and cultured in DMEM medium containing 4.5 g / L glucose, supplemented with 10% FBS, 50 U / mL penicillin and 50 mg / mL streptomycin until the cell confluence reached 80%. 10 μg of the vector plasmid pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro vector carrying the PHOSHO1 gene, 7.5 μg psPAX2 and 3 μg pMD2.G were mixed in 500 μL DMEM and mixed thoroughly. 4 μL Lipofectamine 2000 was added to 500 μL DMEM, inverted to mix, and then allowed to stand for 5 minutes. The plasmid mixture was slowly added dropwise to the liposome mixture, inverted to mix, and allowed to stand for 10 minutes. The final mixture was evenly added to the HEK293T cells, gently shaken to ensure that the transfection mixture was evenly distributed, and then the cell culture dish was returned to the 37°C incubator for further culture for 8-10 hours. The culture medium in each culture dish was replaced with 15 mL of fresh 4.5 g / L glucose DMEM medium containing 5% FBS, 50 U / mL penicillin and 50 mg / mL streptomycin. After continuing to culture for 60 hours, the virus-containing supernatant was collected and filtered through a 0.45 μm needle filter to remove cell debris. The resulting virus was used to infect iPSC-RPE cells. After 2-3 days, GFP expression was examined by fluorescence microscopy to verify the efficiency of viral transfection and successful viral packaging. At the same time, iPSC-RPE cells were transfected with lentivirus carrying an empty vector as a control (Control).

[0047] The overexpression of PHOSPHO1 in iPSC-RPE cells was confirmed by WB and quantitative analysis. Figure 1 A and 1B, PHOSPHO1 expression was significantly increased in iPSC-RPE cells.

[0048] (2) Overexpression of PHOSPHO1 can reduce the PE content in the endoplasmic reticulum of iPSC-RPE cells

[0049] Using Minute TM ER enrichment kit from each sample 2x10 7ER was extracted from cells, and lipid molecules were extracted from ER by ultrasonic disruption using 1 mL of standard lipid extraction solution provided by MetWare Biotechnology. Subsequently, the supernatant was obtained for lipid analysis by centrifugation at 4 °C and 12,000 g for 10 min. 2 μL of sample was separated on Thermo's accucoreTMC30 column at a flow rate of 0.35 mL / min and a column temperature of 45 °C. The elution gradient was set from A / B (80:20, v / v) and then returned to A / B (80:20, v / v) after a series of changes. API6500+ triple quadrupole-linear ion trap mass spectrometer (QTRAP) was used with an electrospray ionization source, and its parameters included turbo spray, source temperature, and ion spray voltage, which provided conditions for the accurate detection of lipid molecules. The quantitative analysis of lipidome was completed by multiple reaction monitoring (MRM) technology.

[0050] Results Figure 2 , overexpression of PHOSPHO1 can reduce the content of PE in the endoplasmic reticulum.

[0051] (3) Overexpression of PHOSPHO1 in iPSC-RPE can enhance its ability to resist ferroptosis

[0052] Cells were evenly seeded in 96-well culture plates at a density of 1500 cells per well. Different concentrations of erastin (0 to 100 μM) or ferric ammonium citrate (FAC) (0 to 1600 μM) were added. After two days of culture, cell viability was measured using CCK-8 reagent. Results are shown in Figure 3 D and 3E, iPSC-RPE cells overexpressing PHOSPHO1 have stronger cell viability. Detection of ROS: The cells were evenly seeded in a 96-well culture plate. The cells were treated with 30μM erastin and 500μM FAC. The culture medium was removed and DMEM / F12 medium containing 10μM DCFH-DA was added to each well in a volume of 50μL. The cells were cultured at 37°C for 60min to allow DCFH-DA to fully penetrate and react with intracellular ROS. The fluorescence intensity was measured using a Multi-Mode MicroplateReader at an excitation wavelength of 488nm and an emission wavelength of 525nm. For results, see Figure 4 F and 4G, Overexpression of PHOSPHO1 can reduce the generation of ROS.

[0053] Example 2. Overexpression of PHOSPHO1 in rat RPE cells can inhibit RPE ferroptosis and protect the retina

[0054] (1) Injection of a virus carrying the Phospho1 gene into the subretinal cavity to overexpress Phospho1 in rat RPE cells

[0055] Virus preparation: SD rats (purchased from Shanghai Slake Experimental Animal Co., Ltd.) were euthanized, and rat testicular tissues were taken and RNA was extracted. After reverse transcription, the rat Phospho1 gene was amplified by PCR. The primers used in PCR were: F: AGCGAATTCGGGATCGCCACCATGTGCCAGCGACCCTGG (SEQ ID NO.3); R: CAGATCCTTGCGGCCTCAGCACATCTTCAGCACCTGTTGC (SEQ ID NO.4). The gene was constructed into the pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro vector according to the method in Example 1 to obtain the vector plasmid pCDH-CMV-MCS-EF1-CopGFP-T2A-Puro carrying the Phospho1 gene, and the virus was further prepared to obtain a lentivirus carrying the Phospho1 gene.

[0056] Model establishment: Six-week-old SD rats were anesthetized with 2% sodium pentobarbital. A 30-gauge needle was inserted into the vitreous cavity from behind the edge of the eyeball to form a channel. A 33-gauge needle was inserted into the subretinal space in the center of the retina, and 3 μL of lentivirus carrying the rat Phospho1 gene was injected. The eyes of the control group were injected with lentivirus carrying an empty vector. Three days later, a 33-gauge needle was inserted into the vitreous cavity, and 2 μL of FAC (1 mM) was injected into the vitreous cavity to induce iron allergy.

[0057] PHOSPHO1 detection: The rats were euthanized, the eyeballs were dissected, and the choroid and RPE cells were further obtained. The expression of PHOSPHO1 was detected by Western blot, and it was confirmed that the expression level of PHOSPHO1 in RPE cells was significantly increased. The results can be found in Figure 5 A and 5B.

[0058] Among them, Western blot is operated as follows:

[0059] (1) Preparation of protein samples: Obtain choroid and RPE tissues, add an appropriate amount of protein lysis buffer RIPA containing protease inhibitors, collect RIPA, centrifuge at 12000rpm for 20 minutes, and take the supernatant. Use BCA quantitative method to determine protein concentration: the concentration of protein standard is 2μg / μL, add protein standard in the order of 0μL, 1μL, 2μL, 4μL, 8μL, 16μL (unit: μL), and fill to 20μL with ddH2O for making standard curve. Take 2μL of sample, fill to 20μL with ddH2O, add 200μL of working solution in the kit to each well, set blank well, and incubate in a constant temperature incubator at 37°C for 30 minutes. The absorbance was read at a wavelength of 562 nm using an enzyme-labeled instrument. The sample concentration was calculated based on the protein standard curve. The protein sample denaturant required for each sample was further calculated. The protein concentration of the sample was adjusted to 1 μg / μL. After preparation, the sample was denatured in a 100°C metal bath for 10 minutes to allow the protein to be repeatedly denatured. After centrifugation, the sample was stored in a -80°C refrigerator.

[0060] (2) Gel preparation: Use a rapid gel preparation kit to prepare 12.5% ​​gel.

[0061] (3) Electrophoresis: After the concentrated gel is solidified, install the tank. Add protein marker and protein sample in sequence to ensure that the protein mass in each well is the same. Generally, the sample volume is 20 μL. Connect the power supply, 80V constant voltage, and adjust the voltage to 110V after 30 minutes. Determine the duration of electrophoresis based on the band size of the target protein.

[0062] (4) Transfer: First, activate the PVDF membrane with methanol and shake it on a shaker for 1 minute. After activation, wash it with 1× TBST solution. The order of placing the membrane for transfer is sponge pad → filter paper → glue → PVDF membrane → filter paper → sponge pad. Turn on the power supply, 300mA constant current, 120 minutes.

[0063] (5) Incubation with antibodies: After transfer, carefully separate the membrane and place it in the 5% BSA blocking solution prepared in advance for 1 hour. Then incubate with the diluted primary antibody in a 4°C refrigerator overnight. Wash the membrane 3 times with 1×TBST on a shaker, 10 minutes each time. Incubate the PVDF membrane with the secondary antibody diluted in 5% BSA at room temperature for 1 hour.

[0064] (6) Chemiluminescence: Mix solution A and solution B in the enhanced chemiluminescence solution (ECL) kit in a ratio of 1:1. Spread the PVDF membrane on the color development plate, drop the mixed working solution on the membrane and place it in the luminometer for luminescence color development. The luminescence solution needs to be prepared before use.

[0065] (2) PHOSPHO1 inhibits RPE cell ferroptosis and protects the retina

[0066] ERG detection: SD rats were dark-adapted overnight (12h-16h), anesthetized by intraperitoneal injection of 2% sodium pentobarbital, muscle relaxation with sudamixin, mydriasis with 0.5% tropicamide and ocular surface anesthesia with 0.4% oxybuprocaine hydrochloride, and electrodes were connected after the pupils of the rats were dilated. The corneal electrode was connected to the cornea of ​​the rats, the reference electrode was connected to the subcutaneous part between the two ears of the rats, and the ground electrode was connected to the subcutaneous part of the tail of the rats. The instrument was operated according to the instrument instructions provided by the manufacturer of visual electrophysiological instrument (Chongqing Kanghua), and 6.325e was used. -2 cd×s / m 2 The light intensity was used to stimulate the rats, and the signals collected were used to calculate the amplitudes of the a and b waves to evaluate the visual function. The entire recording process was completed in a completely dark room, and only red light was used for illumination. Figure 6 C and 6D, Overexpression of PHOSPHO1 increased the amplitudes of a- and b-waves.

[0067] Nuclear layer thickness detection: One week after modeling, the collected eyeball samples were prepared into frozen sections, the cell nuclei were stained with 0.5μg / ml DAPI, and the sections were sealed with fluorescent sealing agent. The structure of the entire retina was photographed using a fluorescent microscope. Ten different positions on the nasal and temporal sides were taken to measure the thickness of the outer nuclear layer (ONL) of the retina. The results can be found in Figure 7 E and 7F, Overexpression of PHOSPHO1 can increase the thickness of the retinal nuclear layer, showing a protective effect on the retina.

[0068] The operation of immunofluorescence staining is as follows:

[0069] The eyeballs were fixed with 4% PFA and frozen sections were made. The samples were blocked with 3% BSA at room temperature for 1 hour, and anti-human 4-HNE primary antibody (abcam) diluted with 3% BSA was added, placed in a humidified box to prevent drying, and incubated at 4°C overnight. Washed with PBS 3 times, 5 minutes each time; added fluorescein-labeled secondary antibody diluted with 3% BSA, placed in a humidified box, incubated at 4°C overnight in the dark, washed with PBS 3 times, 5 minutes each time; 0.5μg / mL LDAPI was used to stain the cell nucleus for 5 minutes, and the slides were sealed with fluorescent sealing agent and observed under a fluorescence microscope. Results are shown in Figure 7 E, Overexpression of PHOSPHO1 can reduce the production of 4-HNE.

[0070] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description.

Claims

1. Use of the phosphoethanolamine / phosphocholine phosphatase 1 gene in the preparation of the drug described in (1) or (2), characterized in that: The drug comprises a vector that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene; (1) Drugs that inhibit ferroptosis of retinal pigment epithelial cells; (2) Drugs for preventing and / or treating age-related macular degeneration.

2. The use according to claim 1, characterized in that The vector is a viral vector; Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.

3. The use according to claim 1, characterized in that The ferroptosis is ferroptosis induced by iron ions.

4. A product as described in any one of the following (1) to (3), characterized in that: (1) The product is a pharmaceutical composition, which comprises a vector that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene; Preferably, the vector is a viral vector; Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector; (2) The product is a cell overexpressing the phosphoethanolamine / phosphocholine phosphatase 1 gene, and the cell is an iPSC-RPE cell or an RPE cell; (3) The product is a rat that overexpresses the phosphoethanolamine / phosphocholine phosphatase 1 gene, and the phosphoethanolamine / phosphocholine phosphatase 1 gene is overexpressed in the RPE cells of the rat.

5. A method for inhibiting ferroptosis of retinal pigment epithelial cells, characterized in that: include: Overexpression of the phosphoethanolamine / phosphocholine phosphatase 1 gene in retinal pigment epithelial cells.

6. The method according to claim 5, characterized in that The phosphoethanolamine / phosphocholine phosphatase 1 gene was overexpressed in retinal pigment epithelial cells by introducing an overexpression vector carrying the phosphoethanolamine / phosphocholine phosphatase 1 gene.

7. The method according to claim 6, characterized in that The overexpression vector is a viral vector; Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.

8. A method for reducing the content of phosphatidylethanolamine in the endoplasmic reticulum of retinal pigment epithelial cells, characterized in that: include: Overexpression of the phosphoethanolamine / phosphocholine phosphatase 1 gene in retinal pigment epithelial cells.

9. The method according to claim 8, characterized in that The phosphoethanolamine / phosphocholine phosphatase 1 gene was overexpressed in retinal pigment epithelial cells by introducing an overexpression vector carrying the phosphoethanolamine / phosphocholine phosphatase 1 gene.

10. The method according to claim 9, characterized in that The overexpression vector is a viral vector; Preferably, the viral vector is a lentiviral vector or an adeno-associated viral vector.